Wednesday, November 11, 2026

KLA Raises 2026 Chip Equipment Forecast to $150B, Citing AI Demand

KLA raised its September-quarter revenue guidance to $4 billion and lifted its 2026 wafer fab equipment market outlook to the low-$150 billion range. The company also raised its advanced packaging revenue target to $1.1 billion and announced a 10-for-1 stock split, pointing to sustained AI chip and HBM memory production growth.

LM Salvado

August 3, 2026

KLA Raises 2026 Chip Equipment Forecast to $150B, Citing AI Demand
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

KLA raised its September-quarter revenue guidance to $4 billion, citing surging demand for AI chip manufacturing equipment.1 The company lifted its 2026 wafer fabrication equipment market forecast to the low-billions range.1

KLA also raised its advanced packaging process control revenue target to billions.1 Advanced packaging tools inspect and measure the multi-chip assemblies used in AI accelerators and high-bandwidth memory (HBM).1 All three revisions came within the same reporting cycle, alongside a 10-for-1 stock split.1

The guidance increase signals equipment makers are booking orders tied directly to AI accelerator fabrication capacity.1 Wafer equipment spending funds the tools that produce logic and memory chips powering AI data centers.1 A billions 2026 market outlook would mark continued growth in capital spending across the chip supply chain.1

The revenue and outlook increases point to sustained order strength for semiconductor capital equipment over the next one to two quarters.1 Rising AI chip fabrication demand is the stated driver.1 Peer equipment makers, including Applied Materials, Lam Research, and ASML, could report similar guidance increases as the same demand flows through their order books.1

Advanced packaging is a bottleneck step in AI chip production, connecting processors to HBM stacks.1 KLA's billions target for that segment signals equipment makers expect packaging capacity, not just wafer fabrication, to expand alongside AI accelerator output.1 Combined with the wider wafer equipment forecast, the guidance suggests capacity expansion is occurring across multiple stages of AI hardware production simultaneously.1

The 10-for-1 stock split does not change the company's underlying business but typically accompanies a period of sustained share price appreciation.1 Together, the guidance raises indicate equipment suppliers are positioning for continued AI-driven capital expenditure into next year.1

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com